5AM Partners VII, LLC - Aug 21, 2025 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
10%+ Owner
Signature
5AM Partners VII, LLC, By /s/ Andrew J. Schwab, Managing Member
Stock symbol
SKYE
Transactions as of
Aug 21, 2025
Transactions value $
-$800,549
Form type
4
Date filed
8/22/2025, 07:05 PM
Previous filing
Sep 13, 2024

Reporting Owners (8)

Name Relationship Address Signature Signature date CIK
5AM Partners VII, LLC 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO 5AM Partners VII, LLC, By /s/ Andrew J. Schwab, Managing Member 2025-08-22 0001873545
5AM Ventures VII, L.P. 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO 5AM Ventures VII, L.P., By: 5AM Partners VII, LLC, its General Partner, By /s/ Andrew J. Schwab, Managing Member 2025-08-22 0001844435
5AM Partners II, LLC 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO 5AM Partners II, LLC, By /s/ Andrew J. Schwab, Managing Member 2025-08-22 0001555952
5AM Ventures II LP 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO 5AM Ventures II, L.P., By: 5AM Partners II, LLC, its General Partner, By /s/ Andrew J. Schwab, Managing Member 2025-08-22 0001386509
5AM CO-INVESTORS II LP 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO 5AM Co-Investors II, L.P., By: 5AM Partners II, LLC, its General Partner, By /s/ Andrew J. Schwab, Managing Member 2025-08-22 0001390376
DIEKMAN JOHN D 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO /s/ John Diekman 2025-08-22 0001240357
PARMAR KUSH 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO /s/ Kush Parmar 2025-08-22 0001664281
ROCKLAGE SCOTT M 10%+ Owner 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO /s/ Scott M. Rocklage 2025-08-22 0001219014

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Sale -$209K -58.6K -3.49% $3.57 1.62M Aug 21, 2025 By 5AM Ventures II, L.P. F1, F2
transaction SKYE Common Stock Sale -$8.26K -2.31K -3.49% $3.57 64K Aug 21, 2025 By 5AM Co-Investors II, L.P. F1, F3
transaction SKYE Common Stock Sale -$561K -164K -10.12% $3.42 1.46M Aug 22, 2025 By 5AM Ventures II, L.P. F2, F4
transaction SKYE Common Stock Sale -$22.1K -6.47K -10.12% $3.42 57.5K Aug 22, 2025 By 5AM Co-Investors II, L.P. F3, F4
holding SKYE Common Stock 8.17M Aug 21, 2025 By 5AM Ventures VII, L.P. F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F3 The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.